LAGOS — While sectors like Banking and Telecoms often steal the spotlight on the Nigerian Exchange (NGX), the healthcare and pharmaceutical sector emerged as one of the most explosive stories of 2025.
Driven by a surge in domestic manufacturing, expanding product lines, and a renewed investor appetite for defensive stocks, Nigerian healthcare companies reached historic valuation milestones.
As of the close of 2025, the sector saw a significant re-rating, with some stocks delivering triple-digit returns that far outpaced the broader market index.
The Healthcare Giants: Market Cap Rankings (End of 2025)
The following companies represent the heavy hitters in Nigeria’s listed healthcare space. Their market capitalization reflects the total value investors placed on their shares by December 31, 2025.
| Rank | Company | Market Cap (End of 2025) | YTD Performance (2025) | Key Driver |
| 1 | MeCure Industries | ₦220 Billion | +296% | Market re-rating and expansion of diagnostic services. |
| 2 | Fidson Healthcare | ₦98.7 Billion | +177% | Dominance in domestic drug manufacturing and resilience. |
| 3 | May & Baker Nigeria | ₦30.7 Billion | +89.4% | Stability in heritage brands and consistent earnings. |
| 4 | Neimeth Pharma | ₦26.3 Billion | +169% | Operational turnaround and massive stock rebound. |
| 5 | Morison Industries | ₦4.6 Billion | +17% | Moderate growth in medical supply segment. |
Inside the 2025 “Healthcare Rally”
1. The MeCure Phenomenon
MeCure Industries was the undisputed “MVP” of the sector in 2025. Opening the year at ₦13.90 and closing near ₦55, the company’s market cap soared to ₦220 billion.
This rally was fueled by the company’s unique position as both a pharmaceutical manufacturer and a leader in high-end medical diagnostics—a sector that saw a surge in demand as more Nigerians sought local alternatives to medical tourism.
2. Fidson’s Manufacturing Muscle
Fidson Healthcare solidified its status as a “Financial Fortress” within the sector. With a nearly 180% gain, Fidson benefitted from the government’s push for local drug production to curb foreign exchange pressures on imported medicines.
Its ₦98.7 billion valuation makes it the largest traditional “pure-play” drug manufacturer on the exchange.
3. Neimeth’s Remarkable Comeback
After several years of subdued performance, Neimeth International Pharmaceuticals became a favorite for momentum traders in 2025. Its stock price rose from ₦2.29 to ₦6.15.
The rally was underpinned by a successful rights issue and the modernization of its Oregun manufacturing facility, which signaled to investors that the company was ready to scale.
The “Why” Behind the Growth
- Import Substitution: As the Naira stabilized in 2025, companies with strong local manufacturing plants (like Fidson and May & Baker) were able to capture market share from expensive imported brands.
- Resilient Demand: Healthcare is a defensive sector; even in tough economic climates, spend on medicine and diagnostic services remains a priority for households.
- Institutional Interest: In 2025, local institutional investors (PFAs) shifted more weight into healthcare stocks to diversify away from the highly volatile financial services sector.
Nigeria Healthcare Sector
2025 was the year Nigeria’s healthcare sector moved from being a “market laggard” to a “growth engine.”
While the sector still lacks a ₦1 trillion “SWOOT” (Stocks Worth Over One Trillion), the rise of MeCure toward the ₦250 billion mark suggests that the healthcare industry is finally achieving the scale needed to attract global institutional capital.
